A real‐world, non‐interventional, prospective study of the effectiveness and safety of apremilast in bio‐naïve adults with moderate plaque psoriasis treated in the routine care in Greece – the 'APRAISAL' study. (21st May 2022)

• Record Type: Journal Article
• Authors: Ioannides, D.; Antonakopoulos, N.; Chasapi, V.; Oikonomou, C.; Tampouratzi, E.; Lazaridou, E.; Rigopoulos, D.; Neofotistou, O.; Drosos, A.; Anastasiadis, G.; Rovithi, E.; Kalinou, C.; Papadavid, E.; Aronis, P.; Papageorgiou, M.; Protopapa, A.; Bassukas, I.; Lefaki, I.; Zafiriou, E.; Krasagakis, K.; Pokas, E.; Anagnostopoulos, Z.; Kekki, A.; Papakonstantis, M.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 36:Number 11(2022)
• Page Start: 2055
• Page End: 2063
• Publication Date: 2022-05-21
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.18166
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: Real‐world data in patients with moderate psoriasis treated with apremilast is limited. Objectives: To evaluate the effectiveness and safety of apremilast in bio‐naïve patients with moderate psoriasis in real‐world clinical settings. Methods: This was a 52‐week multicenter, observational, prospective study of adult outpatients with moderate psoriasis {[10% < body surface area < 20% or 10 < psoriasis area severity index (PASI) < 20] and 10 < dermatology quality of life index (DLQI) < 20} initiated on apremilast ≤7 days before enrollment. Missing data were imputed using the last observation carried forward method. Results: A total of 287 eligible patients (median age: 54.2 years; median psoriasis duration: 9.8 years) were consecutively enrolled. At baseline, the median DLQI and PASI scores were 12.0 and 11.8, respectively. The 52‐week DLQI ≤ 5 and PASI75 response rates were 68.3% and 61.0%. At 52 weeks, 70.8% and 72.7% of the patients shifted from moderate/severe/very severe to clear/minimal scalp and palmoplantar psoriasis involvement, respectively; the pruritus severity state improved in 67.2%. The 52‐week Kaplan–Meier estimated drug continuation rate was 85.3%. The adverse drug reaction rate was 19.9%. Conclusions: Apremilast is a safe and effective treatment for bio‐naïve patients with moderate psoriasis and specific psoriasis manifestations.